Johnson & Johnson study identifies mouth dryness as top symptom priority for Sjögren's patients
JNJ•Johnson & Johnson said patients in a Phase 2 study of nipocalimab identified mouth dryness as the symptom they most wanted improved. Two Phase 3 studies are ongoing, and previously reported Phase 2 results showed improved saliva production versus placebo, with reduced disease activity and severity.
1. Patient priorities
Johnson & Johnson said new Phase 2 patient-experience findings identified mouth dryness as the symptom Sjögren's disease patients most wanted improved. The findings are to be presented at the American College of Rheumatology Convergence 2026.
2. Ongoing trials
Previously reported Phase 2 results showed improved saliva production versus placebo, with reduced disease activity and severity. Two Phase 3 studies are ongoing and incorporate measures of symptoms and outcomes important to patients.
